Avalanche Biotechnologies, an ocular gene therapy company based in Menlo Park California, have announced the completion of a $55M fund raising. The company will use… Read More »US ocular gene therapy company, Avalanche Biotechnologies, raises $55M in a Series B fund-raising
A surveillance and epidemiological study, conducted by the US National Cancer Institute (NCI), has shown that recent trends indicate an excess of total retinoblastoma among… Read More »Changing incidence of retinoblastoma highlighted in US epidemiology study
Research scientists based at the University of California, Berkeley, the University of Bonn, Germany and the University of Alabama, Birmingham, have published research in which… Read More »German-US collaborative research suggests photoreceptors may act individually to shape perception
Oxford Biomedica plc, (LSE: OXB), a UK-based biopharmaceutical company has announced the completion of a planned recruitment of 21 patients into its Phase I trial… Read More »Oxford Biomedica plc restarts Phase I gene therapy study for neovascular wet AMD
Dompe Pharmaceuticals, an Italian biopharmaceutical company based in L’Aquila, Italy, have announced the initiation of a 24-week, double-blind, vehicle-controlled, Phase Ib/II clinical study to evaluate… Read More »Dompe recruits first patient for trial of recombinant human nerve growth factor in treatment of reti
Scientists based at the University of California, Berkeley, the University of Washington, Seattle, and the University of Munich, Germany have collaboratively published results of a… Read More »Neuron paper shows restoration of vision in blind animals using a small molecule photoswitch
Applied Genetic Technologies Corporation, Inc., (AGTC), a Florida-based rare ophthalmic disease company has raised just over $50 million in its IPO debut on the US… Read More »Retinal gene therapy company, Applied Genetic Technologies Corporation (NASDAQ:AGTC), raises $50M in IPO
Germany’s Federal Joint Committee have issued a final benefit assessment in respect of Bayer’s Eylea aflibercept (VEGF Trap Eye) stating that the Regeneron Inc., drug… Read More »German regulator sees no additional benefit for Eylea over Lucentis in macular edema secondary to CRVO
Organisers behind the ProgStar Study, a natural history study of the course of Stargardt’s disease, have announced that it will now include patients carrying a… Read More »Natural history study of Stargardt’s disease to include very rare forms of the condition
Reuters news agency have reported that Italian prosecutors have opened a formal investigation against Roche (SIX: ROG; OTCQX:RHHBY), Basel, Switzerland and Novartis AG (NYSE: NVS;… Read More »Reuters report Italian investigation into Roche and Novartis executives over Lucentis